with breast cancer has
every year worldwide
a woman is diagnosed with HER2+ breast cancer
Human Epidermal Growth Factor
Receptor-2 Positive is
one of the most
of breast cancer
HER2+ breast cancer is a
clinical unmet need
To date, there are no tools to predict
the beneficial effect of targeted therapy
and the risk of recurrence
HER2DX® measures the expression of 27 genes
from Formalin-Fixed, Paraffin-Embedded (FFPE) breast cancer tissues.
Specifically, HER2DX® evaluates the following biological processes:
The biological information from these 4 gene signatures is combined
with clinical data such as tumor stage and nodal stage.
References:- A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer:a retrospective study with an external evaluation. Prat A, et al. Lancet Oncol. 2020 Nov;21(11):1455-1464.